[go: up one dir, main page]

WO1996019580A3 - Telomerase protein component - Google Patents

Telomerase protein component Download PDF

Info

Publication number
WO1996019580A3
WO1996019580A3 PCT/US1995/016531 US9516531W WO9619580A3 WO 1996019580 A3 WO1996019580 A3 WO 1996019580A3 US 9516531 W US9516531 W US 9516531W WO 9619580 A3 WO9619580 A3 WO 9619580A3
Authority
WO
WIPO (PCT)
Prior art keywords
protein component
telomerase
methods
telomerase protein
activity
Prior art date
Application number
PCT/US1995/016531
Other languages
French (fr)
Other versions
WO1996019580A2 (en
Inventor
Carol Greider
Kathleen Collins
Ryuji Kobayashi
Xiaohong Helena Yang
Jill M Hemish
Chantal Autexier
Original Assignee
Cold Spring Harbor Lab
Carol Greider
Kathleen Collins
Ryuji Kobayashi
Xiaohong Helena Yang
Jill M Hemish
Chantal Autexier
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cold Spring Harbor Lab, Carol Greider, Kathleen Collins, Ryuji Kobayashi, Xiaohong Helena Yang, Jill M Hemish, Chantal Autexier filed Critical Cold Spring Harbor Lab
Priority to JP8519939A priority Critical patent/JPH10513343A/en
Priority to EP95943470A priority patent/EP0799315A2/en
Publication of WO1996019580A2 publication Critical patent/WO1996019580A2/en
Publication of WO1996019580A3 publication Critical patent/WO1996019580A3/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K2217/00—Genetically modified animals
    • A01K2217/05—Animals comprising random inserted nucleic acids (transgenic)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Oncology (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Biotechnology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • General Engineering & Computer Science (AREA)
  • Virology (AREA)
  • Microbiology (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)

Abstract

Genes encoding the amino acid sequences of the protein component of Tetrahymena telomerase and methods for their preparation and use are disclosed. The protein component is comprised of two subunit polypeptides, and 80 kD and a 95 kD polypeptide. Methods for deducing the protein component of human telomerase and its uses are also described. The telomerase protein component may be used to develop diagnostic procedures for detection of telomerase activity in cancers, microbial diseases, and other disorders, and to produce therapeutic compounds to inhibit or enhance telomerase activity.
PCT/US1995/016531 1994-12-19 1995-12-18 Telomerase protein component WO1996019580A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
JP8519939A JPH10513343A (en) 1994-12-19 1995-12-18 Telomerase protein components
EP95943470A EP0799315A2 (en) 1994-12-19 1995-12-18 Telomerase protein component

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US35912594A 1994-12-19 1994-12-19
US08/359,125 1994-12-19

Publications (2)

Publication Number Publication Date
WO1996019580A2 WO1996019580A2 (en) 1996-06-27
WO1996019580A3 true WO1996019580A3 (en) 1996-08-29

Family

ID=23412425

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1995/016531 WO1996019580A2 (en) 1994-12-19 1995-12-18 Telomerase protein component

Country Status (3)

Country Link
EP (1) EP0799315A2 (en)
JP (1) JPH10513343A (en)
WO (1) WO1996019580A2 (en)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6517834B1 (en) 1995-08-04 2003-02-11 Geron Corporation Purified telomerase
US5968506A (en) * 1995-08-04 1999-10-19 Geron Corporation Purified telomerase
US6545133B1 (en) 1995-08-04 2003-04-08 Geron Corporation Methods for purifying telomerase
AU2593697A (en) * 1996-03-28 1997-10-17 Albert Einstein College Of Medicine Of Yeshiva University Transgenic organisms with altered telomerase activity
US5747317A (en) * 1996-07-08 1998-05-05 Tularik Inc. Human telomerase RNA interacting protein gene
US5770422A (en) * 1996-07-08 1998-06-23 The Regents Of The University Of California Human telomerase
US6808880B2 (en) 1996-10-01 2004-10-26 Geron Corporation Method for detecting polynucleotides encoding telomerase
US7585622B1 (en) 1996-10-01 2009-09-08 Geron Corporation Increasing the proliferative capacity of cells using telomerase reverse transcriptase
NZ334709A (en) * 1996-10-01 2001-06-29 Univ Technology Corp Detection of hTRT activity or expression and use in the treatment of cancer
US6475789B1 (en) 1996-10-01 2002-11-05 University Technology Corporation Human telomerase catalytic subunit: diagnostic and therapeutic methods
US6261836B1 (en) 1996-10-01 2001-07-17 Geron Corporation Telomerase
US6610839B1 (en) 1997-08-14 2003-08-26 Geron Corporation Promoter for telomerase reverse transcriptase
US6093809A (en) * 1996-10-01 2000-07-25 University Technology Corporation Telomerase
US5919656A (en) 1996-11-15 1999-07-06 Amgen Canada Inc. Genes encoding telomerase protein 1
US7390891B1 (en) 1996-11-15 2008-06-24 Amgen Inc. Polynucleotides encoding a telomerase component TP2
CA2285672C (en) * 1997-04-04 2012-01-31 Geron Corporation Purified telomerase
US7413864B2 (en) 1997-04-18 2008-08-19 Geron Corporation Treating cancer using a telomerase vaccine
US7622549B2 (en) 1997-04-18 2009-11-24 Geron Corporation Human telomerase reverse transcriptase polypeptides
WO1998059040A2 (en) * 1997-06-20 1998-12-30 Bayer Aktiengesellschaft Human catalytic telomerase sub-unit and its diagnostic and therapeutic use
EP1571215A3 (en) * 1997-07-01 2007-10-31 Cambia Biosystems LLC Vertebrate telomerase genes and proteins and uses thereof
CA2294782A1 (en) 1997-07-01 1999-01-14 Cambia Biosystems Llc Vertebrate telomerase genes and proteins and uses thereof
US7378244B2 (en) 1997-10-01 2008-05-27 Geron Corporation Telomerase promoters sequences for screening telomerase modulators
US6995145B1 (en) 1999-06-04 2006-02-07 Au Jessie L-S Methods and compositions for modulating drug activity through telomere damage
US6399384B1 (en) 1999-09-17 2002-06-04 Reneuron Limited Conditional immortalization of cells
US7078491B1 (en) 2000-09-21 2006-07-18 Amgen Inc. Selective binding agents of telomerase
WO2012104987A1 (en) * 2011-02-01 2012-08-09 国立大学法人福島大学 Enzyme and method of production therefor
JP6245570B2 (en) * 2013-10-08 2017-12-13 国立研究開発法人理化学研究所 Trypanosoma-related disease therapeutic agent, trypanosome protozoan killing method and use thereof

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023572A1 (en) * 1992-05-13 1993-11-25 University Of Texas Southwestern Medical Center At Dallas Therapy and diagnosis of conditions related to telomere length and/or telomerase activity

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1993023572A1 (en) * 1992-05-13 1993-11-25 University Of Texas Southwestern Medical Center At Dallas Therapy and diagnosis of conditions related to telomere length and/or telomerase activity

Non-Patent Citations (6)

* Cited by examiner, † Cited by third party
Title
AUTEXIER, C. ET AL.: "Functional reconstitution of wild-type and mutant Tetrahymena telomerase.", GENES AND DEVELOPMENT, (1994 MAR 1) 8 (5) 563-75, XP002004672 *
BLACKBURN, E.H.: "Structure and function of telomeres", NATURE, vol. 350, 18 April 1991 (1991-04-18), LONDON GB, pages 569 - 573, XP002004674 *
COLLINS, K. ET AL.: "Purification of Tetrahymena telomerase and cloning of genes encoding the two protein components of the enzyme.", CELL, (1995 JUN 2) 81 (5) 677-86, XP002004675 *
HARRINGTON, LEA ANNE: "Characterization and purification of Tetrahymena telomerase", December 1993, PH.D THESIS PRESENTED AT THE STATE UNIVERSITY OF NEW YORK AT STONY BROOK, XP002004676 *
STRAHL, C. ET AL.: "The effects of nucleoside analogs on telomerase and telomeres in Tetrahymena.", NUCLEIC ACIDS RESEARCH, (1994 MAR 25) 22 (6) 893-900, XP002004673 *
UNIV. MICROFILMS INT., ORDER NO. DA9417761 FROM: DISS. ABSTR. INT. B 1994, 55(2), 279 *

Also Published As

Publication number Publication date
WO1996019580A2 (en) 1996-06-27
JPH10513343A (en) 1998-12-22
EP0799315A2 (en) 1997-10-08

Similar Documents

Publication Publication Date Title
WO1996019580A3 (en) Telomerase protein component
WO1995007992A3 (en) Cloned glutamic acid decarboxylase
CA2219988A1 (en) Cd16-ii variants
ZA943464B (en) Vascular endothelial growth factor 2
CA2257133A1 (en) Human dnase i hyperactive variants
EP0278776A3 (en) Methods and deoxyribonucleic acid for the preparation of tissue factor protein
CA2064689A1 (en) Stabilized protein or peptide conjugates
IL114987A0 (en) Modulators of body weight, corresponding nuclic acid and proteins, and diagnostic and therapeutic uses thereof
WO1998055508A3 (en) HUMAN PROTEINS HAVING TRANSMEMBRANE DOMAINS AND DNAs ENCODING THESE PROTEINS
EP1063293A3 (en) Transforming growth factor alpha H1
HK102192A (en) Human tumor necrosis factor and dna therefor
EP0909814A3 (en) Use of protein kinases for the diagnosis and treatment of Alzheimer's disease
WO1998021232A3 (en) Mutant forms of fas ligand and uses thereof
NZ279963A (en) Human tissue inhibitor of metalloproteinase-4 (timp-4) and dna (rna) encoding polypeptide which may be derived from atcc 75946
DE69221486D1 (en) BOMBESIN ANALOG
WO2000053749A3 (en) Vascular adhesion molecules and modulation of their function
ES8605476A1 (en) Enzyme-protein conjugate, process for its preparation and pharmaceutical use thereof.
CA2154080A1 (en) Novel anticoagulant cofactor activity
HU902004D0 (en) New trombolitic preparations
WO1999033989A3 (en) Rantes mutants and therapeutic applications thereof
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
AU1318797A (en) Peptides and uses thereof for therapy of celiac diseases
WO2003014293A3 (en) Novel polypeptide analogs and fusions and their methods of use
WO1999030670A3 (en) Methods of treatment using novel ligands of the neuropeptide receptor hfgan72 and agonists or antagonists thereof
CA2210871A1 (en) Human dnase i variants

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): CA JP MX US

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
121 Ep: the epo has been informed by wipo that ep was designated in this application
ENP Entry into the national phase

Ref country code: US

Ref document number: 1997 797401

Date of ref document: 19970210

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 1995943470

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 1995943470

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1995943470

Country of ref document: EP